By Adriano Marchese
Neuronetics shares jumped in premarket trading Tuesday after the company said it expects revenue to double from 2024 levels, rising above analyst expectations.
Shares traded 15% higher at $4.89.
For the full-year 2025, the medical device company expects total worldwide revenue to be between $145 million and $155 million. This is up from $74.9 million in 2024, and higher than the $93.5 million forecasted by analysts, according to FactSet.
Gross margins are projected to be 55%, while operating expenses are expected to fall within the range of $90 million to $98 million.
More immediately, in the first quarter, Neuronetics expects total revenue between $28 million and $30 million.
This is up from its latest fourth-quarter results where it generated $22.5 million in revenue, up from $20.3 million, beating analyst projections of a slight decline to $19.6 million and its own guidance range of between $19 million and $20 million.
Net loss in the quarter widened to $12.2 million from $5.4 million, which on a oer-share basis was a loss of 33 cents compared with a loss of 19 cents.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.